Effects of dietary Bacillus coagulans and yeast hydrolysate supplementation on growth performance, immune response and intestinal barrier function in weaned piglets.
- 2021-03-14
- Journal of Animal Physiology and Animal Nutrition 105(5)
- Runqi Fu
- Chan Liang
- Daiwen Chen
- H. Yan
- G. Tian
- P. Zheng
- Jun He
- Jie Yu
- X. Mao
- Zhiqing Huang
- Yuheng Luo
- Junqiu Luo
- B. Yu
- PubMed: 33715204
- DOI: 10.1111/jpn.13529
Abstract
The present study investigated the effects of Bacillus coagulans and yeast hydrolysate supplementation on growth performance, immune response and intestinal barrier function of weaned piglets. Twenty-four weaned piglets with an average body weight (BW) of 6.89 ± 0.15 kg were divided into four diets for 28 days. The treatments were basal diet (control), basal diet supplemented with antibiotic (20 mg/kg colistin sulphate and 40 mg/kg bacitracin zinc, AT), probiotics (400 mg/kg Bacillus coagulans ≥5 × 109 CFU/g, BC) or yeast hydrolysate (5000 mg/kg yeast hydrolysate, YH). Average daily gain (ADG) and average daily feed intake (ADFI) were improved by AT and YH diets (p < 0.05), while BC diet only increased ADG (p < 0.05). The complement 3 (C3), lysozyme (LZM) and tumour necrosis factor-α (TNF-α) concentrations in serum were increased in BC diet (p < 0.05). Feeding AT and YH caused the increase of jejunal villus height (p < 0.05), and a higher ratio of villus height/crypt depth was observed in AT, BC and YH groups (p < 0.05). The mRNA expression of zonula occludens-1 (ZO-1) in jejunal mucosa was up-regulated by AT, BC and YH diets (p < 0.05). Dietary AT, BC or YH inclusion decreased the interleukin-1β (IL-1β) concentration and TNF-α mRNA expression (p < 0.05), and YH supplementation even down-regulated toll-like receptor 4 (TLR4) and CD14 expressions (p < 0.05). In summary, the dietary administration of BC or YH both improves growth performance through promoting the intestinal barrier function, indicating both of them can serve as potential alternatives to antibiotics growth promoters for the piglet production.
Keywords: Bacillus coagulans; growth performance; immune function; intestinal barrier; weaned piglets; yeast hydrolysate.
Research Insights
Supplement | Health Outcome | Effect Type | Effect Size |
---|---|---|---|
Bacillus coagulans | Improved Average Daily Gain | Beneficial | Moderate |
Bacillus coagulans | Increased Serum Complement 3 (C3) Levels | Beneficial | Moderate |
Bacillus coagulans | Increased Serum Lysozyme Levels | Beneficial | Moderate |
Bacillus coagulans | Increased Tumor Necrosis Factor-Alpha Levels | Beneficial | Moderate |
Bacillus coagulans | Increased Villus Height to Crypt Depth Ratio | Beneficial | Moderate |
Bacillus coagulans | Increased ZO-1 mRNA Expression in Jejunal Mucosa | Beneficial | Large |
Bacillus coagulans | Reduced Interleukin-1β Levels | Beneficial | Moderate |
Bacillus coagulans | Reduced Tumour Necrosis Factor-α (TNF-α) mRNA Expression | Beneficial | Moderate |
Bacillus coagulans LactoSpore 1 billion CFU | Improved Growth Performance | Beneficial | Moderate |
Bacillus coagulans LactoSpore 1 billion CFU | Improved Immune Response | Beneficial | Moderate |
Bacillus coagulans LactoSpore 1 billion CFU | Improved Intestinal Barrier Function | Beneficial | Moderate |
Bacillus coagulans LactoSpore 1 billion CFU | Reduced Inflammatory Markers | Beneficial | Moderate |
Bacillus coagulans MTCC 5856 | Improved Growth Performance | Beneficial | Moderate |
Bacillus coagulans MTCC 5856 | Improved Immune Response | Beneficial | Moderate |
Bacillus coagulans MTCC 5856 | Improved Intestinal Barrier Function | Beneficial | Moderate |
Bacillus coagulans MTCC 5856 | Reduced Inflammatory Markers | Beneficial | Moderate |
Bacillus coagulans ProDura | Improved Immune Response | Beneficial | Moderate |
Bacillus coagulans ProDura | Improved Intestinal Barrier Function | Beneficial | Moderate |
Bacillus coagulans ProDura | Reduced Inflammatory Markers | Beneficial | Moderate |
Bacillus coagulans SC208 | Improved Growth Performance | Beneficial | Moderate |
Bacillus coagulans SC208 | Improved Immune Response | Beneficial | Moderate |
Bacillus coagulans SC208 | Improved Intestinal Barrier Function | Beneficial | Moderate |
Bacillus coagulans SC208 | Reduced Inflammatory Response | Beneficial | Moderate |
Bacillus coagulans SNZ-1969 | Improved Growth Performance | Beneficial | Moderate |
Bacillus coagulans SNZ-1969 | Improved Immune Response | Beneficial | Moderate |
Bacillus coagulans SNZ-1969 | Improved Intestinal Barrier Function | Beneficial | Moderate |
Bacillus coagulans SNZ-1969 | Reduced Inflammatory Markers | Beneficial | Moderate |
Bacillus coagulans Unique IS-2 | Increased Average Daily Gain | Beneficial | Moderate |
Bacillus coagulans Unique IS-2 | Increased Serum Complement 3 (C3) Levels | Beneficial | Moderate |
Bacillus coagulans Unique IS-2 | Increased Serum Lysozyme Levels | Beneficial | Moderate |
Bacillus coagulans Unique IS-2 | Increased Serum Tumor Necrosis Factor-α Levels | Neutral | Small |
Bacillus coagulans Unique IS-2 | Increased Villus Height to Crypt Depth Ratio | Beneficial | Moderate |
Bacillus coagulans Unique IS-2 | Increased ZO-1 mRNA Expression in Jejunal Mucosa | Beneficial | Large |
Bacillus coagulans Unique IS-2 | Reduced Interleukin-1β Concentration | Beneficial | Small |
Bacillus coagulans Unique IS-2 | Reduced TNF-α mRNA Expression | Beneficial | Small |